Crestline Management’s DexCom DXCM Stock Holding History

Crestline Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8,000	Closed	-$1.07M	–	277
2021 Q4	$1.07M	Buy	+8,000	New	+$1.15M	0.08%	139

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Crestline Management's DXCM Position: Q1 2025 in Review

Crestline Management sold out of DexCom (DXCM) in Q1 2025, closing a stake of 13,591 shares — an estimated $1.06M sold.

Crestline Management first reported a position in DXCM in Q3 2021 and held it in 3 quarters. The position peaked at $2.64M in Q3 2021. 932 funds tracked by Wall St. Rank hold DXCM as of Q1 2025.

Crestline Management reported no remaining DexCom position as of Q1 2025 after selling out during the quarter.
Crestline Management sold 13,591 DexCom shares in Q1 2025, an estimated $1.06M.
Crestline Management first reported a position in DexCom in Q3 2021 and held it in 3 quarters.
Crestline Management's DexCom position peaked at $2.64M in Q3 2021.
932 funds tracked by Wall St. Rank held DexCom as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.